The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients (2004)

Peer-Reviewed Study · Tier 1 — Primary Document · Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. · October 2004

Ludwig H et al., 2004-10: Prospective survey of 15,367 European cancer patients followed up to six months. Anaemia prevalence was 39.3% at enrolment and 67.0% during the survey; only 38.9% of anaemic patients were treated.

Prevalence of anaemia at enrollment was 39.3% (haemoglobin <10.0 g/dL, 10%), and 67.0% during the survey (haemoglobin <10.0 g/dL, 39.3%).

Abstract

Ludwig H et al., 2004-10: Prospective survey of 15,367 European cancer patients followed up to six months. Anaemia prevalence was 39.3% at enrolment and 67.0% during the survey; only 38.9% of anaemic patients were treated. Comparator: none (observational survey of mixed tumour types and treatments, chemotherapy subgroup reported separately in the full text). Funder: not stated in the abstract and the full text was not opened this run; the survey is widely described as industry-supported (erythropoietin-era), but that is unconfirmed here and the verifier should read the paper's acknowledgement section before repeating it. The 67% overall prevalence does not support 'up to 90%'; the 90% figure was not found in any document this run. Study type: uncontrolled series.